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April 30, 2013:1831–4p  0.006) and diameter stenosis (26.69  20.38% vs. 32.31 
16.66%; p  0.06) at follow-up were better in the PES arm in the
“in-stent/balloon” analysis. Interestingly, these differences were not
detected in the “in-segment” analysis, suggesting the possibility of an
“edge phenomenon” after PES. Although not powered for clinical
events, the current study was large, timely, and nicely executed, and it
provides novel insights clearly supporting the value of DEB in patients
with SVD. Nevertheless, further studies are warranted to demonstrate
that DEB outperform PES, or are equivalent to second-generation
drug-eluting stents, before they would be widely adopted in this
challenging anatomic scenario (5,6).
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Reply
We thank Dr. White and colleagues and Dr. Alfonso and colleagues
for their interest in the BELLO (Balloon Elution and Late Loss
Optimization) study, which is to date the largest randomized trial to
compare drug-eluting balloons (DEB) with drug-eluting stents in de
novo small-vessel disease (1). We agree that there is an intrinsic
methodological weakness in comparing late loss with a device known
to produce a large immediate gain (stent) versus a device producing a
smaller initial gain (balloon) and therefore a lower late loss. This
situation has been demonstrated historically in the seminal studies of
stent versus balloon angioplasty (2,3), in which the late loss after
balloon angioplasty was about one-half of the late loss with a
bare-metal stent (about 0.3 mm vs. 0.6 mm). In our study, we face a
similar situation but with a difference in the fourth magnitude. This
finding cannot be dismissed by the simple statement that the “lower
you gain, the less you lose.” The fact that the late loss after DEB was4 times lower than after drug-eluting stents suggests, as expected, that
other mechanisms (the drug on the balloon) are in action to lower the
percentage of late loss compared with the small gain. This fact is
further supported by the lack of difference in binary restenosis
numerically and statistically.
Furthermore, we would like to take the opportunity to highlight
the absolute value of late loss after DEB in BELLO (0.08 0.38 mm).
This value is considerably lower than the values seen with competitor
DEBs in de novo disease: 0.32  0.56 mm overall and 0.18  0.38
mm for DEB only in the PEPCAD I (Paclitaxel-Eluting PTCA-
Balloon to Treat Small Vessel) study (4) or the 0.38  0.39 mm
(personal communication, January 2013, from Eurocor GmbH) result
found in the Valentines Trial II. We want to take the opportunity in
this letter to reaffirm that we are not claiming superiority of a balloon
procedure compared with a drug-eluting stent procedure regarding
final and follow-up lumen dimensions. Instead, our goal is to provide
data supporting the possibility of using an alternative procedure
(DEB) in situations in which stenting may not be considered ideal.
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Potential Impact of Concomitant
Valvular Lesions and Coronary
Artery Bypass Surgery on
Outcome in Low-Gradient
Severe Aortic Stenosis With
Preserved Ejection Fraction
We read with interest the study by Clavel et al. (1). The investigators
sought to compare outcomes among 3 groups of patients: those
with the syndrome of paradoxical low-flow, low-gradient (LF/LG)
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April 30, 2013:1831–4severe aortic stenosis (AS), those with moderate AS, and those
with high-gradient severe AS. Although the study provides in-
triguing new data on the subject, there was no mention of how the
investigators dealt with concomitant valvular heart disease (i.e.,
mitral regurgitation, stenosis, or tricuspid regurgitation). This
raises concerns that the results described in the report may not
truly represent the entity of paradoxical LF/LG severe AS.
Concomitant valvular heart disease can result in reduced for-
ward left ventricular stroke volume, resulting in a state of low flow.
In this situation, the etiology of reduced flow is different from that
of paradoxical LF/LG severe AS described by Clavel et al. (1) as a
combination of small left ventricular cavity, intrinsic myocardial
dysfunction, and increased afterload. Without correcting for other
causes of low flow (i.e., excluding patients with concomitant
valvular heart disease) as others have done (2,3), it is uncertain
whether the results of this study truly describe paradoxical LF/LG
severe AS, which has garnered so much interest recently.
Additionally, concomitant coronary artery bypass graft surgery
was performed in 53% of patients in the LF/LG severe AS group,
compared with 39% in the high-gradient severe AS group.
Coronary artery disease but not coronary artery bypass graft
surgery was considered in the event-free survival and survival
analyses. Concomitant coronary artery bypass graft surgery would
be expected to increase operative mortality.
Concomitant valvular disease may have multiple confounding
effects on patient outcomes, including the hemodynamic effects
that make AS severity grading a challenge and lead to delays in
treatment. Both concomitant valvular disease and severe coro-
nary artery disease may have independent effects on patient
mortality and may affect surgical complexity and periprocedural
outcomes. Future studies in the interesting group of patients
with paradoxical LF/LG severe AS should consider the impact
of these comorbidities.
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We thank Drs. Eleid and Pellikka for their insightful comments
with regard to our study and for giving us the opportunity to
provide more information in this regard.
Paradoxical low-flow, low-gradient (PLF/LG) aortic stenosis
(AS) is defined by the constellation of a low-flow state (i.e., strokevolume index 35 ml/m2) despite a normal left ventricular (LV)
ejection fraction, a small aortic valve area (1.0 cm2; indexed
ortic valve area 0.6 cm2/m2) suggesting severe AS, and a low
radient (40 mm Hg) (1). The most prevalent form of PLF/LG
S is characterized by increased global LV hemodynamic load,
ronounced LV concentric remodeling with small LV cavity size,
estrictive physiology leading to impaired LV filling, and altered
ongitudinal myocardial systolic function (1). All these factors
ontribute to the reduced LV outflow and the worse outcomes
bserved in these patients (1,2). However, as correctly underlined
y Drs. Eleid and Pellikka, other mechanisms may also contribute
o the occurrence of a low-flow state and adverse events in patients
ith AS with preserved LV ejection fraction including concomi-
ant mitral regurgitation, tricuspid regurgitation, and/or coronary
rtery disease. In our study, patients with more than mild mitral
egurgitation were excluded, so we cannot conclude on the impact
f this factor (2). In addition, 4.6% of the patients had more than
ild tricuspid regurgitation, with no significant difference among
he PLF/LG AS, high-gradient severe AS, and moderate AS
roups. The presence of more than mild tricuspid regurgitation
as not significantly associated with worse outcomes in this study.
The studies that examined the impact of concomitant coronary
rtery bypass graft surgery on outcomes in patients undergoing
ortic valve replacement (AVR) yielded conflicting results. Some
tudies found that concomitant coronary artery bypass graft surgery
s associated with increased mortality, whereas others reported that
t is protective in patients with PLF/LG AS (1). Furthermore, the
ompleteness of revascularization may also have an impact on the
utcomes of these patients. In our study, concomitant coronary
rtery bypass graft surgery was not significantly associated with
urvival after AVR (p  0.64) (2).
Besides increased afterload and restrictive LV physiology, other
factors may contribute to the PLF/LG pattern. The presence of a low
gradient in the context of a preserved LV ejection fraction may, in
turn, lead to an underestimation of AS severity and therefore underuse
or inappropriate delay of AVR in these patients (1). There is now
obust evidence that patients with PLF/LG severe AS have a worse
rognosis and that AVR improves outcomes in these patients (1,2).
ence, as recommended in the recent guidelines of the European
ociety of Cardiology and the European Association for Cardio-
horacic Surgery (3), proper recognition of PLF/LG AS is crucial and
VR should be considered (Class IIa recommendation) in these patients
fter careful confirmation of stenosis severity. Future studies are needed to
etermine the impact of comorbidities on the outcomes of patients with
LF/LG AS and to better identify those who are likely to benefit from
urgical AVR. Furthermore, it remains to be determined if transcatheter
VR may be a better alternative in some of these patients.
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